Form 4 for TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD

Accepted 2026-09-22 16:21:45 ET · period of report 2026-09-19 · accession 0001193125-26-397959 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
I	2026-09-22 16:21	2026-09-18	TEVA	MIGNONE ROBERTO	Dir	S - Sale	$39.06	-367.6K	0	-100%	-$14.36M

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Ordinary Shares	2026-09-18	S	D	367,600	$39.06	0	I [see footnote]	—	—	(F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.68 to $39.38, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. (F2) The 367,600 Ordinary Shares disclosed in Table I of this Form 4 were held of record by Swiftcurrent Master Fund Ltd. (the "Fund"). Bridger Management, LLC is the investment adviser to the Fund and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone was deemed to beneficially own the Ordinary Shares held of record by the Fund. Mr. Mignone disclaimed beneficial ownership of the Ordinary Shares held of record by the Fund except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone was the beneficial owner of the Ordinary Shares held of record by the Fund for purposes of Section 16, or for any other purpose.